Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genetic Signatures Ltd. ( (AU:GSS) ) has issued an announcement.
Genetic Signatures reported unaudited second-quarter FY26 sales of $3.3 million, reflecting a seasonal downturn in respiratory testing in Australia, with revenue contributions now coming from Australia, EMEA and the US and a rising share from international markets. Customer receipts reached $4.6 million and net operating cash inflow was $1.8 million, bolstered by an Australian R&D tax incentive, leaving the company with a strong total cash and term deposit position of $29.7 million at 31 December 2025 to fund ongoing operations and development. Operationally, the company advanced implementation of its EasyScreen™ Gastrointestinal Parasite Detection Kit at three initial US customer sites that are now acting as reference centres to drive further adoption, while in the UK its gastrointestinal test kits are gaining momentum with National Health Service trusts, supported by positive clinical data and increased usage in infection control and outbreak prevention. The company also continued development of an automated, high-throughput integrated instrument and software platform, including procurement of a non-customised instrument to expand its 3base® infectious disease testing menu, positioning it for future product launches and potential growth in key international markets.
The most recent analyst rating on (AU:GSS) stock is a Sell with a A$0.22 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.
More about Genetic Signatures Ltd.
Genetic Signatures Ltd is an Australian molecular diagnostics company that develops and commercialises infectious disease testing solutions, including its EasyScreen™ and 3base® syndromic testing range. The company services clinical laboratories and hospital networks across Australia, Europe, the Middle East and Africa (EMEA), and the United States, with a growing focus on gastrointestinal and respiratory pathogen detection for public and private healthcare providers.
Average Trading Volume: 202,321
Technical Sentiment Signal: Sell
Current Market Cap: A$52.24M
Find detailed analytics on GSS stock on TipRanks’ Stock Analysis page.